21 October - 3 November 2017
These are links to news stories from the last week that may be of interest to people in the UK. The link beneath each item will take you to the original story.
Please note that the MS Trust did not write the original items and does not endorse their content nor any claims made in them.
To keep up to date on all the latest news, views and research on multiple sclerosis, sign up for Open Door, our free newsletter or regular email alerts
Gilenya effective as treatment for teens with MS
A study found that Gilenya (fingolimod) reduced the relapse rate in people with MS aged between 10 and 18 by 82% over two years compared to Avonex (interferon beta 1a). This is the first randomised controlled trial in people of this age group
MS Trust link: Childhood MS
Zinbryta liver damage restrictions
A committee of the European Medicines Agency has recommended limiting the use of Zinbryta (daclizumab). The change follows a safety reviews prompted by evidence of potentially fatal liver problems. The recommendation is that the drug is only used with people where two other disease modifying drugs (DMD) have been unsuccessful and for whom there are no other DMD options.
MS Trust link: MS Decisions - a guide to treatments for relapsing MS
Having other health conditions delays MS diagnosis
A Danish study looked at people whose first MS symptoms appeared between 1980 and 2005. Having other health conditions (comorbidities) as well as MS both extended the time between first symptoms and diagnosis, and increased the risk of dying sooner
Source: Neurology Advisor
MS Trust link: MS research updates